Cingulate Inc. (CING)
4.17
-0.08 (-1.88%)
At close: Apr 02, 2025, 3:59 PM
4.14
-0.72%
After-hours: Apr 02, 2025, 07:42 PM EDT
-1.88% (1D)
| Bid | 3.8 |
| Market Cap | 15.71M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -4.84 |
| PE Ratio (ttm) | -0.86 |
| Forward PE | -0.89 |
| Analyst | Buy |
| Ask | 4.48 |
| Volume | 53,835 |
| Avg. Volume (20D) | 136,755 |
| Open | 4.27 |
| Previous Close | 4.25 |
| Day's Range | 4.00 - 4.23 |
| 52-Week Range | 1.80 - 20.83 |
| Beta | -0.84 |
About CING
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety diso...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 8, 2021
Employees 13
Stock Exchange NASDAQ
Ticker Symbol CING
Website https://www.cingulate.com
Analyst Forecast
According to 3 analyst ratings, the average rating for CING stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 283.69% from the latest price.
Stock Forecasts4 months ago
+9.27%
Cingulate shares are trading higher after Maxim Gr...
Unlock content with
Pro Subscription
6 months ago
-8.76%
Cingulate shares are trading lower. The company announced it commenced its final FDA-required study, which is a food effect study, for CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder.
